Clinical trials: Covid-19 Pneumonia
Coronavirus Disease (COVID-19)
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
This study is a long-term follow-up survey of Japanese people after their second vaccination with the Moderna COVID-19 vaccine. The study sponsor will not be involved in how the participants are treated but will provide…
- Trial name
- NCT04941144
- Testing
- COVID-19 Vaccine
- Where
- Japan
- Volunteers
- 8,538 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, Pregnancy Related
Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
The proposed study is designed to investigate if and how pregnant women infected with Coronavirus Disease-19 (COVID-19) infection go on to develop long-term immunity.
- Conditions
- COVID-19, Pregnancy Related, Influenza, Human
- Trial name
- ImmunoCOVID (NCT04568044)
- Testing
- Blood sample
- Where
- 2 sites in United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Imperial College London
SARS-CoV-2 Infection, Cognitive Change
The ACDC Study Assessing Cognitive Deterioration in COVID-19
The long-term impact and effects of COVID-19 are still being determined. However, what is clear, is that some people are still struggling following a period of illness with COVID-19.
- Conditions
- SARS-CoV-2 Infection, Cognitive Change, Cognitive Dysfunction
- Trial name
- ACDC (NCT05855434)
- Testing
- Magnetic Resonance Imaging
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- NHS Grampian
COVID-19, ARDS
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
COVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a dysregulated immune response.
- Trial name
- NCT04401475
- Testing
- SOC plus 15mg/kg EB05 IV
- Where
- 20 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Edesa Biotech Inc.
COVID-19 Vaccines
COVID-19 Booster Dose Reminder/Recall for Adolescents
A single COVID-19 booster dose has been recommended in the United States for adolescents aged ≥12 years to enhance protection against SARS-CoV-2 infection.
- Trial name
- AIMED COVID (NCT05571657)
- Testing
- Reminder/Recall Sent Via Preferred Method of Communication
- Where
- United States
- Volunteers
- 4,304 people
- Sponsor
- Marshfield Clinic Research Foundation
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID19, Acute Renal Failure
The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
Aim of the study is to determinate the frequency of acute renal failure in COVID-19 patients, its relationship with the severity of COVID-19 disease in ICU, and the ability to take precautions against these factors.
- Trial name
- NCT04799600
- Testing
- BRESCİA-COVİD Respiratory Severity Scale
- Where
- Turkey (Türkiye)
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent
COVID-19
Improving COVID-19 Vaccine Uptake Among Black and Latino Youth
Black and Latino youth may be less likely to get the COVID-19 vaccine than White youth. In this study we will work with community members to come up with ways to help Black and Latino families learn more about the COVID-19…
- Trial name
- NCT05293392
- Testing
- Culturally-Tailored COVID-19 Vaccine Uptake Intervention, Standard Care
- Where
- United States
- Volunteers
- 5,792 people
- Sponsor
- Nemours Children's Health System
COVID-19, Outcome, Fatal
Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application
In a retrospective observational study, critically ill COVID-19 patients admitted to the ICU with the CoV-2 delta-variant between august 2021 and february 2022 were evaluated (ethics application nr.
- Conditions
- COVID-19, Outcome, Fatal, Tocilizumab, Interleukin 6
- Trial name
- CasiTocCOVID (NCT06233357)
- Testing
- treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)
- Where
- Germany
- Volunteers
- 95 people
- Sponsor
- University of Ulm
Covid19
Oral Manifestations of Coronavirus Disease 2019(COVID-19) :a Multicentre Study
online questionnaire will be distributed in different country to detect the oral change in patient diagnosed with COVID-19
- Trial name
- NCT04487665
- Volunteers
- 50 people
- Sponsor
- Cairo University
Colorectal Neoplasms Malignant
Effects of COVID-19 Pandemic on the Outcomes of Colorectal Cancer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been identified as the cause of the Coronavirus disease 19 (COVID-19), which was initially reported in December 2019 in China and has since rapidly spread…
- Trial name
- COVID-CRC (NCT04712292)
- Testing
- Surgical procedure for confirmed or suspected colorectal cancer
- Where
- 45 sites in Italy
- Volunteers
- 15,000 people
- Sponsor
- University of Bologna
RSV Infection, Covid19
Respiratory Syncytial Virus Infection May be More Dangerous in Neonate
Investigators aimed to compare clinical and radiographic markers between SARS-CoV-2 positive and RSV positive infants
- Trial name
- NCT04531735
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Dr. Behcet Uz Children's Hospital
COVID-19, SARS-CoV-2
Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)
Lymphopenia is common in patients with COVID-19 and is associated with worse clinical outcomes. NT-I7 is a long-acting human interleukin-7 (IL-7) that has been shown to increase absolute lymphocyte count (ALC) and CD4+ and CD8+ T…
- Trial name
- NCT04498325
- Testing
- NT-I7, Blood for research purposes, Blood for pharmacokinetic samples
- Sponsor
- Washington University School of Medicine
Ischemic Stroke, Covid 19
Endovascular Thrombectomy in COVID-19 Infected Patients
About 5% of COVID-19 patients may present symptoms related to acute ischemic stroke (AIS). Treatment-management and outcomes related to mechanical thrombectomy (MT) for COVID-19 infected patients harboring large vessel occlusion…
- Trial name
- ET-COVID-19 (NCT04406090)
- Testing
- Mechanical Trombectomy
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Montpellier
COVID-19
A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19
COVID-19 virus remains in infected patients for extended periods of time. A great resource burden is placed on the healthcare system and society at large to isolate COVID-19 patients for prolonged periods.
- Trial name
- NCT04433013
- Testing
- Lianhua Qingwen
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nanyang Technological University
Covid19
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
- Trial name
- DAMPENCOVID (NCT04445285)
- Testing
- Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase), 0.9%sodium chloride
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Jon Simmons
Covid19
Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19
The purpose of this study is to assess the safety and efficacy of UNI91103 intranasal spray for treatment of coronavirus disease 2019 (COVID-19) in asymptomatic or mildly symptomatic adults.
- Trial name
- PREVENT (NCT04932915)
- Testing
- Niclosamide
- Where
- 3 sites in Germany
- Volunteers
- 4 people
- Sponsor
- UNION therapeutics
COVID-19
Max COVID19- Study
In view of the increasing cases of COVID-19 in India and the possibility of the exponential rise of the cases, this study has been designed to collect data of the healthcare workers of Max Hospital and the general population.
- Trial name
- NCT04339608
- Where
- India
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Max Healthcare Insititute Limited
Covid19
Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose
CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA.
- Trial name
- CombiVacS (NCT05378191)
- Testing
- COMIRNATY
- Where
- 5 sites in Spain
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Covid19
COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020
The management of the Grand Hôpital de Charleroi hospital authorized the performance of a serology for each member of the establishment's staff in order to better characterize the proportion of its employees who have already been…
- Trial name
- NCT04723290
- Testing
- Serological tests for SARS Cov-2
- Where
- Belgium
- Volunteers
- 2,817 people, healthy volunteers welcome
- Sponsor
- Grand Hôpital de Charleroi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.